Exercise liberates us, motivates us, and improves both our physical and mental health.

Today, those who are unable to exercise, miss out on those benefits.

We want to change that.

Imitex is developing new pharmaceutical therapies that replicate many of the key beneficial biochemical and genetic changes that naturally occur when people exercise.

Our goal is to help people who are unable exercise, due to illness, injury or age, in their journey to health, wellness and recovery. We aim to do this stimulating the body’s own natural biochemical and genetic responses to exercise that prove so beneficial for those that can move

The health of your muscles has a major impact on the health of your organs, tissues and different systems throughout your body.

Recent research has identified that many of the key biochemical and physiological changes that occur when people exercise, start with changes in gene expression.

We have been able to replicate some of those biochemical and physiological changes in preclinical animal studies by developing drugs to replicate those changes in gene expression.

We are currently working on optimising these promising drug candidates with the aim of delivering the benefits of exercise to those who need it the most; those living with illnesses such as muscular dystrophies, the injured and the aged.

Imitex has developed a proprietary evaluation system, our SPRINT technology platform, to make our promising starting drug suitable for long term use.

Imitex believes a drug that is able to provide some of the benefits of exercise could improve the lives of patients with a wide range of healthcare conditions.

Muscular Dystrophies

There are a range of inherited muscle degenerative diseases that characterised by muscle wastage and atrophy. Of particular interest are Facioscapulohumeral muscular dystrophy (FSHD), Duchenne muscular dystrophy (DMD) and Kennedy’s disease (SBMA). These, and other similar conditions are characterised by ongoing muscle wastage eventually leading to tremors, loss of mobility, and often respiratory failure leading to death. Imitex’s approach offers the promise of ameliorating muscle wastage, enabling improvements to musculo-skeletal tone, and associated secondary (metabolic pathways).


Sarcopenia is age-related loss of skeletal muscle mass and function, leading to physical disability, poor quality of life and eventually death. Sarcopenia negatively impacts many seniors, and can lead to loss of mobility, increased risk of falls and an associated loss of independence.  Whilst the incidence and societal cost of sarcopenia are well understood, there are currently no therapeutics approved to treat this debilitating condition. Imitex’s approach, based on a detailed understanding of the molecular processes that drive muscle strengthening, offer new solutions to this condition.

Company leadership

Greg Collier PhD
Executive Chairman

Former CEO 25+ years Biotech experience
Avecho Biotechnology​ and TessaraTherapeutics​
Formerly Chem Genex Pharmaceuticals

Sean McGee PhD
Director and CSO

Professor of Medical Biology, Deakin University
20+ years researching the MEF2-class IIa HDAC axis

Andrew F Wilks PhD
Non Executive Director

More than 40 years experience in cancer research, medicinal chemistry and entrepreneurship.
Co-founder and CEO of SYNthesis Research. Formerly Cytopia

James CampbellPhD MBA
Corporate Advisor

20+ years Biotech experience​
CEO of Patrys Limited​
Director of Prescient Therapeutics​
Formerly Evolve Biosystems​ Inc

Dr Tom Gumley
Intellectual Property Manager

Biotech patent specialist​
20+ years working with Australian biotech companies​
Registered patent attorney​

Contact us

35/37 Gordon Avenue
Geelong West VIC 3218

Your Name *
Fill out this field
Email Address *
Please enter a valid email address.
Your Message *
Fill out this field
25 - 5 = ?
Enter the equation result to proceed